Compare DHI & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | IDXX |
|---|---|---|
| Founded | 1978 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.4B | 45.4B |
| IPO Year | 1995 | 1996 |
| Metric | DHI | IDXX |
|---|---|---|
| Price | $144.41 | $528.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $166.08 | ★ $721.67 |
| AVG Volume (30 Days) | ★ 1.6M | 484.0K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ 22.59 |
| EPS | 7.45 | ★ 7.74 |
| Revenue | ★ $34,250,400,000.00 | $4,303,702,000.00 |
| Revenue This Year | $0.05 | $10.88 |
| Revenue Next Year | $5.85 | $8.59 |
| P/E Ratio | ★ $19.10 | $69.64 |
| Revenue Growth | N/A | ★ 10.42 |
| 52 Week Low | $131.75 | $518.55 |
| 52 Week High | $183.62 | $769.98 |
| Indicator | DHI | IDXX |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 38.41 |
| Support Level | $138.27 | N/A |
| Resistance Level | $153.01 | $583.93 |
| Average True Range (ATR) | 3.23 | 14.63 |
| MACD | -0.62 | -2.68 |
| Stochastic Oscillator | 19.21 | 6.09 |
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.